Get the Stockscreener App
28.13
1.82%
-0.52
After Hours:
28.50
0.37
+1.32%
Apellis Pharmaceuticals Inc stock is traded at $28.13, with a volume of 2.81M.
It is down -1.82% in the last 24 hours and up +16.24% over the past month.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
See More
Previous Close:
$28.65
Open:
$28.84
24h Volume:
2.81M
Relative Volume:
1.24
Market Cap:
$3.55B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-13.86
EPS:
-2.03
Net Cash Flow:
$-205.58M
1W Performance:
+2.03%
1M Performance:
+16.24%
6M Performance:
+8.19%
1Y Performance:
-28.40%
1-Day Range:
$27.84
$28.97
1-Week Range:
$27.14
$28.97
52-Week Range:
$16.10
$41.94
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Name
Apellis Pharmaceuticals Inc
Sector
Industry
Phone
617-977-5700
Address
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
28.13 | 3.62B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-09-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-21-24 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-25-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-16-24 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Neutral |
| Feb-05-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-02-23 | Initiated | Mizuho | Neutral |
| Oct-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-29-23 | Reiterated | Citigroup | Buy |
| Aug-03-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-01-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-22 | Initiated | H.C. Wainwright | Buy |
| Jun-17-22 | Resumed | Stifel | Buy |
| Apr-14-22 | Downgrade | ROTH Capital | Neutral → Sell |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-10-21 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-21 | Reiterated | Credit Suisse | Neutral |
| Sep-10-21 | Reiterated | Needham | Buy |
| Sep-10-21 | Reiterated | Oppenheimer | Outperform |
| Sep-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Aug-19-21 | Initiated | Jefferies | Buy |
| Aug-19-21 | Upgrade | Wedbush | Neutral → Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Nov-19-20 | Initiated | Needham | Buy |
| Sep-01-20 | Initiated | Stifel | Buy |
| Jul-20-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| Apr-01-20 | Initiated | Raymond James | Strong Buy |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-11-20 | Upgrade | Wedbush | Underperform → Neutral |
| Jan-07-20 | Initiated | SVB Leerink | Mkt Perform |
| Dec-19-19 | Initiated | BofA/Merrill | Buy |
| Nov-22-19 | Initiated | Wedbush | Underperform |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Aug-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-30-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| May-24-18 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
Analyzing net buyer seller activity in Apellis Pharmaceuticals Inc.2025 Market Overview & Verified High Yield Trade Plans - Newser
What makes Apellis Pharmaceuticals Inc. stock attractive todayPortfolio Risk Report & Free Community Consensus Stock Picks - خودرو بانک
What is Apellis Pharmaceuticals Inc.’s valuation compared to sectorJuly 2025 EndofMonth & Weekly Watchlist for Consistent Profits - خودرو بانک
Should I hold or sell Apellis Pharmaceuticals Inc. nowJuly 2025 Breakouts & Free Safe Entry Trade Signal Reports - خودرو بانک
Using data filters to optimize entry into Apellis Pharmaceuticals Inc.Weekly Trade Analysis & Consistent Growth Stock Picks - Newser
Order flow analysis tools used on Apellis Pharmaceuticals Inc.July 2025 Update & Safe Entry Point Alerts - Newser
Automated trading signals detected on Apellis Pharmaceuticals Inc.Earnings Recap Summary & AI Driven Stock Movement Reports - Newser
Has Apellis Pharmaceuticals Inc. formed a bullish divergenceEarnings Performance Report & Real-Time Chart Breakout Alerts - Newser
How Apellis Pharmaceuticals Inc. stock performs during market volatility2025 Technical Patterns & Consistent Income Trade Recommendations - Newser
Using fundamentals and technicals on Apellis Pharmaceuticals Inc.Quarterly Profit Report & Real-Time Volume Analysis - Newser
Analyzing drawdowns of Apellis Pharmaceuticals Inc. with statistical toolsJuly 2025 Momentum & Stepwise Entry/Exit Trade Alerts - Newser
Transcript : Apellis Pharmaceuticals, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-04-2025 08 - MarketScreener
Can Apellis Pharmaceuticals Inc. deliver alphaJuly 2025 Short Interest & Free Real-Time Market Sentiment Alerts - خودرو بانک
Apellis Pharmaceuticals shares fall 2.01% premarket after presenting at Wells Fargo 20th. - AInvest
Apellis Pharmaceuticals Inc. stock retracement – recovery analysisChart Signals & Reliable Price Action Trade Plans - Newser
Backtesting results for Apellis Pharmaceuticals Inc. trading strategiesTrade Risk Assessment & Daily Volume Surge Trade Alerts - Newser
Will Apellis Pharmaceuticals Inc. stock benefit from interest rate changesRate Cut & AI Optimized Trading Strategy Guides - Newser
What earnings revisions data tells us about Apellis Pharmaceuticals Inc.July 2025 Action & Weekly Return Optimization Alerts - Newser
Can machine learning forecast Apellis Pharmaceuticals Inc. recoveryMarket Performance Report & Long-Term Capital Growth Strategies - Newser
Apellis Pharma VP Chopas sells $15k in shares - Investing.com
Can trapped investors hope for a rebound in Apellis Pharmaceuticals Inc.Buy Signal & Comprehensive Market Scan Insights - Newser
What’s the MACD signal for Apellis Pharmaceuticals Inc.Trade Risk Assessment & Weekly High Return Forecasts - خودرو بانک
Transcript : Apellis Pharmaceuticals, Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-03-2025 08 - MarketScreener
What data driven models say about Apellis Pharmaceuticals Inc.’s futureEarnings Miss & Short-Term High Return Strategies - Newser
How is Apellis Pharmaceuticals Inc. managing supply chain issuesWeekly Trend Recap & Growth Focused Stock Reports - خودرو بانک
Should value investors consider Apellis Pharmaceuticals Inc.July 2025 News Drivers & Community Consensus Stock Picks - خودرو بانک
What’s the beta of Apellis Pharmaceuticals Inc. stockQuarterly Earnings Summary & Fast Entry Momentum Alerts - خودرو بانک
Key metrics from Apellis Pharmaceuticals Inc.’s quarterly dataJuly 2025 PostEarnings & Reliable Momentum Entry Alerts - Newser
What’s the profit margin of Apellis Pharmaceuticals Inc.Dollar Strength & Real-Time Stock Movement Alerts - خودرو بانک
Is Apellis Set for a Rebound? - timothysykes.com
Is Apellis Pharmaceuticals Inc. stock a value trap2025 Earnings Impact & High Return Trade Guides - خودرو بانک
Will Apellis Pharmaceuticals Inc. stock recover after recent dropRecession Risk & Safe Capital Investment Plans - Newser
Is Apellis Pharmaceuticals Inc. meeting your algorithmic filter criteriaOptions Play & Consistent Profit Focused Trading Strategies - Newser
Published on: 2025-09-01 23:36:26 - Newser
What the charts say about Apellis Pharmaceuticals Inc. today2025 Performance Recap & Entry Point Strategy Guides - Newser
What to do if you’re stuck in Apellis Pharmaceuticals Inc.Market Activity Summary & Expert Verified Stock Movement Alerts - Newser
How cyclical is Apellis Pharmaceuticals Inc.’s revenue streamMarket Sentiment Report & Entry and Exit Point Strategies - خودرو بانک
Published on: 2025-09-01 19:43:22 - Newser
Real time social sentiment graph for Apellis Pharmaceuticals Inc.Quarterly Trade Review & Reliable Entry Point Alerts - Newser
Has Apellis Pharmaceuticals Inc. found a price floor2025 Market Outlook & Low Drawdown Momentum Trade Ideas - Newser
Apellis Pharmaceuticals Inc. Recovery Gathers Momentum on Chart Signals getLinesFromResByArray error: size == 0 - 강소기업뉴스
Is Apellis Pharmaceuticals Inc. reversing from oversold territoryWeekly Profit Recap & Daily Oversold Stock Bounce Ideas - Newser
How to track smart money flows in Apellis Pharmaceuticals Inc.July 2025 Trends & Precise Swing Trade Entry Alerts - Newser
Have Insiders Sold Apellis Pharmaceuticals Shares Recently? - simplywall.st
Apellis Pharmaceuticals Inc. stock momentum explained2025 Top Gainers & Smart Allocation Stock Tips - Newser
Apellis Pharmaceuticals Inc Stock (APLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):